Skip to content

Author

Nath Adulkasem

3 papers indexed here

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Open access Jul 2026

A Comparison of Clinical Outcomes Among Undenatured Collagen Type II, Glucosamine Sulfate, and Diacerein on Osteoarthritic Knee Treatment: A Randomized Clinical Trial

Background: Knee osteoarthritis (OA) causes significant disability with limited effective treatments. Undenatured collagen type II (UC-II), prescription-grade crystalline glucosamine sulfate (pCGS), and diacerein have been proposed as alternatives to conventional analgesics, but their comparative efficacy remains uncer...

Rapeepat Narkbunnam, Kit Awirotananon, K. Chareancholvanich et al. · 0 citations
Open access Aug 2026

A system-independent 3D coordinate–based planning method for hexapod deformity correction: a synthetic bone model study and preliminary clinical experience

Computer-assisted hexapod external fixators rely on system-specific planning software that is closely linked to the hardware configuration. This may limit flexibility in construct design and cross-system application. A three-dimensional (3D) coordinate–based planning method was developed to allow deformity correction...

Nath Adulkasem, Bavornrit Chuckpaiwong, D. Tantigate et al. · 0 citations
Open access Aug 2026

Prevalence and diagnostic reclassification of sarcopenia in type 2 diabetes according to AWGS 2019 and AWGS 2025 criteria: a secondary cross-sectional analysis

Sarcopenia is common in patients with type 2 diabetes mellitus (T2DM). In 2025, the Asian Working Group for Sarcopenia (AWGS) updated its diagnostic criteria by removing physical performance from the diagnostic algorithm and introducing BMI-adjusted appendicular skeletal muscle mass (ASM). These changes may influ...

Pitchaporn Phudphong, Kwanchanok Laoticharoen, Nath Adulkasem · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.